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Abstract
Severe ADAMTS13 deficiency occurs in 13% to 75% of thrombotic microangiopathies (TMA). In this context, the early
identification of a severe, antibody-mediated, ADAMTS13 deficiency may allow to start targeted therapies such as B-
lymphocytes-depleting monoclonal antibodies. To date, assays exploring ADAMTS13 activity require skill and are limited to
only some specialized reference laboratories, given the very low incidence of the disease. To identify clinical features which
mayallowtopredictrapidlyanacquiredADAMTS13deficiency,weperformedacross-sectionalanalysisofournational registry
from 2000 to 2007. The clinical presentation of 160 patients with TMA and acquired ADAMTS13 deficiency was compared with
that of 54 patients with detectable ADAMTS13 activity. ADAMTS13 deficiency was associated with more relapses during
treatment and with a good renal prognosis. Patients with acquired ADAMTS13 deficiency had platelet count ,30610
9/L
(adjustedoddsratio[OR]9.1,95%confidenceinterval[CI]3.4–24.2,P,.001),serumcreatininelevel#200 mmol/L(OR23.4,95%
CI 8.8–62.5, P,.001), and detectable antinuclear antibodies (OR 2.8, 95% CI 1.0–8.0, P,.05). When at least 1 criteria was met,
patients with a severe acquired ADAMTS13 deficiency were identified with positive predictive value of 85%, negative
predictive value of 93.3%, sensitivity of 98.8%, and specificity of 48.1%. Our criteria should be useful to identify rapidly newly
diagnosed patients with an acquired ADAMTS13 deficiency to better tailor treatment for different pathophysiological groups.
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Introduction
Thrombotic microangiopathies (TMA) represent a rare and
heterogeneous group of diseases defined by microangiopathic
hemolytic anemia with peripheral thrombocytopenia and organ
failure of variable severity. TMA encompass thrombotic throm-
bocytopenic purpura (TTP), typically characterized by central
nervous system (CNS) involvement, and hemolytic uremic
syndrome (HUS) in which severe renal involvement is the
prominent abnormality. TMA may also be associated with various
conditions such as pregnancy, human immunodeficiency virus
(HIV) infection, cancer and chemotherapy, transplantation or
medications.
TTP results from excessive platelet aggregation in multiple
organs with, consequently, a dramatical increase in shear stress
caused by the accumulation of unfolded high-molecular weight
von Willebrand factor multimers in plasma. Failure to process
these multimers into smaller, less adhesive forms is related to a
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this process (Figure S1). ADAMTS13 deficiency may result from
mutations of the encoding gene or from autoantibodies in the
acquired form [1]. Autoantibodies may alter enzyme function
through two nonexclusive mechanisms. The first mechanism is a
direct neutralizing effect, as evidenced by functional in vitro
assays in which plasma from patients with TTP inhibits
ADAMTS13 activity in normal human plasma. The second
mechanism is an opsonization process, involving the formation of
immune complexes with ADAMTS13, which are subsequently
cleared by phagocytes [2,3]. Severe ADAMTS13 deficiency was
reported in 33% to 90% of patients with TTP, whereas
ADAMTS13 activity was found usually normal or slightly
reduced in patients with HUS or other causes of thrombocyto-
penia [4–10]. ADAMTS13 deficiency on diagnosis was reported
to be associated with a better survival, though in those studies
patients with a detectable ADAMTS13 activity usually had
confounding factors such as associated severe conditions involved
in cytopenias and organ injury, which precludes definitive
conclusions [10].
The involvement of ADAMTS13 in TTP pathophysiology
opens the promising perspective of targeted therapies in
association with the current, plasma-based, standard therapy. In
particular, these include immunomodulatory drugs that allow
depleting autoreactive B lymphocytes in patients with acquired,
antibody-mediated ADAMTS13 deficiency. In that regard, the
humanized anti-CD20 monoclonal antibody rituximab produced
high levels of response in patients with refractory or relapsing
acquired TTP [11–13] as a second line treatment. In contrast, the
efficiency of rituximab in TMA with a detectable ADAMTS13
activity remains uncertain. Thus, future therapeutic assays
involving immunomodulation as a first line treatment will
reasonably be targeted first to patients with an autoantibody-
mediated severe ADAMTS13 deficiency. In this regard, the early
administration of rituximab in acquired severe ADAMTS13
deficiency-associated TTP recently showed encouraging results
by limiting treatment duration in slow responders with a non
optimal response to standard plasma exchange (PE)-based
treatment through a faster and durable increase in ADAMTS13
activity ([14] and manuscript submitted).
Therefore, the rapid recognition of a severe acquired
ADAMTS13 deficiency is necessary 1) to facilitate the early
diagnosis of TTP and 2) to identify a subgroup of patients who
may be the best target for future assays evaluating the place of
immunomodulators in the therapeutic scheme. Today, many
methods are available to measure ADAMTS13 activity as a first
line test and anti-ADAMTS13 IgG as a second line test if
ADAMTS13 activity id found markedly decreased [1]. Among
these methods, the one using the FRETS-VWF73 substrate [15]
combines both rapidity and reliability. However, until now, all
ADAMTS13-related assays still belong to the field of medical
research and have not been validated as routine tests. For this
main reason and also for cost issues, the ADAMTS13-related
assays are not accessible to any laboratory and remain limited to
specialized expert laboratories. Furthermore, considering the low
incidence of TMA and especially TTP [10], the national plans for
rare diseases organized in various countries recommend that
specialized analysis dedicated to these pathologies remain
centralized in a very limited number of university hospital
laboratories. As ADAMTS13 activity measurement is crucial to
document in any patient with a TMA suspicion, that means that
some hospitals will not be able to beneficiate of the ADAMTS13
assay locally in emergency although this would facilitate the early
diagnosis and management of TTP.
We and others previously reported from a preliminary
retrospective study that idiopathic autoimmune TTP with a
documented severe acquired ADAMTS13 deficiency was charac-
terized by more severe thrombocytopenia, mild renal involvement
[16,17 and more recently 18], and various immunopathological
features [16,19]. However, whether specific clinical and laboratory
manifestations may be used to predict accurately and rapidly
ADAMTS13 dysfunction has not been evaluated so far. Thus, the
primary objective of this study was to establish a score to predict
ADAMTS13 severe deficiency using standard clinical and
biological parameters. In that regard, we performed a cross-
sectional analysis of our national Registry from 2000 to 2007
allowing the analysis of 214 patients with idiopathic TMA. As a
secondary objective of this study, we focused on both initial clinical
presentation and short term outcome as a function of ADAMTS13
activity to evaluate the relevance of a pathophysiology-based
classification of TMA to guide future therapeutic assays.
Methods
Study Design
The TMA Registry of the French Reference Center for the
management of thrombotic microangiopathies (www.cnr-mat, in
preparation) was established in October 2000 to prospectively and
systematically collect comprehensive clinical and biological data on
patients with various forms of TMA and to create a repository
including plasma and mononuclear cells on diagnosis and
during follow-up (http://www.orpha.net/consor/cgi-bin/index.
php?lng=FR, key-word: PTT or TTP). To manage patients with
TMA consistently throughout our country and to have a
comprehensive registry, we officially defined at least one leading
academic center in each French region (members listed in
appendix). All defined centers, as well as their respective affiliated
regional centers, are involved in the management of patients with
TMA in concert with the reference center, according to consensual
recommendations or results of clinical trials (http://asso.orpha.net/
ORPHAWEB/cgi-bin/file/Plan_Maladies_Rares.pdf).
In the present work, adult (.18 years old) patients were studied
prospectively from October 2000 to October 2007; they were
recruited consecutively and nonselectively from intensive care
units and departments of hematology, internal medicine and
nephrology in 17 leading French centers and their respective
affiliated regional centers. Patients treated for an initial diagnosis
of idiopathic TMA and in whom an associated condition was
diagnosed were subsequently excluded from the current study.
Patients with severe (,5% of normal activity) ADAMTS13
deficiency were compared for clinical, biological, and immuno-
pathological features to patients with detectable ($20%)
ADAMTS13 activity. Patients with an ADAMTS13 activity
between 5–20% in whom either inhibitory or non-inhibitory
anti-ADAMTS13 antibodies were detectable were considered as
having a acquired mild ADAMTS13 deficiency and were included
in the group of patients with a undetectable ADAMTS13 activity.
Patients and Treatment
All adult patients who satisfied the following diagnostic criteria
for TMA were enrolled in the study. This study was approved
by the Saint-Antoine Hospital Ethical committee/Institutional
review board (http://www.orpha.net/consor/cgi-bin/ResearchTrials_
RegistriesMaterials.php?lng=FR&data_id=30475&Nome%20del%
20registro%20di%20materiali=Registre-du-reseau-d-etude-des-
microangiopathies-thrombotiques&title=Registre-du-reseau-d-etude-des-
microangiopathies-thrombotiques&search=ResearchTrials_
RegistriesMaterials_Simple). Written informed consent was ob-
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Coombs-negative microangiopathic hemolytic anemia (schistocytes
on peripheral blood smear) and acute thrombocytopenia
(,150610
9/L). Patients with TMA were excluded if organ failure
and cytopenias may have been related to an associated condition
and not only to the microangiopathic process, that is, solid organ or
hematopoietic stem cell transplant, cancer and chemotherapy, the
syndrome of hemolysis, elevated liver enzymes, and low platelet
count (HELLP), active systemic lupus erythematosus (SLE) or
systemic sclerosis, HIV infection and severe sepsis [16]. Treatment
was administered per protocol according to written recommenda-
tions detailed in previous studies [20,21] and irrespective of
ADAMTS13 activity and anti-ADAMTS13 antibodies status.
Analysis
Data were collected on diagnosis for each patient as previously
described [16]. All data were collected using an established
questionnaire and recorded in a computerized databank.
Blood collection, plasma preparation, and measurement of
ADAMTS13 activity were performed as previously described [6].
ADAMTS13 activity was considered undetectable if ,5% of
normal activity. Inhibitory anti-ADAMTS13 antibodies were
sought in patients when ADAMTS13 activity was ,20%. Since
2006, anti-ADAMTS13 antibodies were sought by ELISA as
previously described [3] when ADAMTS13 activity was ,20%. In
some patients included before 2006, anti-ADAMTS13 antibodies
were sought by ELISA retrospectively from our serum collection.
ADAMTS13 deficiency was considered acquired if associated with
detectable inhibitor and/or anti-ADAMTS13 antibodies, or if
ADAMTS13 deficiency recovered completely or partially ($20%)
after remission. Anti-ADAMTS13 IgG titer was considered
positive for values .15 U/mL. In patients with anti-ADAMTS13
IgG titer at the limit of the positivity threshold (15 to 20 U/mL),
ADAMTS13 activity was investigated during remission, and the
diagnosis of acquired ADAMTS13 deficiency was retained with
certainty in patients for whom ADAMTS13 activity recovered
completely or partially.
Definitions
Response to treatment was defined from previous works on the
basis of the experience of various National centers, and were in
part published elsewhere [21]. A complete response was defined as
the disappearance of possible neurological manifestations and
complete platelet count recovery (.150610
9/L) for at least 2 days
and durable remission was a complete response that persisted
more than 30 consecutive days from the first day of platelet count
recovery (this period of time included the maintenance treatment
by TPE). The time to durable remission was defined as the
number of days from the first day of treatment to the first day from
which platelet count did not worsen for at least 30 consecutive
days. Relapse was defined as the reappearance of neurological
manifestations and/or a recurrence of thrombocytopenia
(,100610
9/L at least 2 days) without any other identifiable
cause, after durable remission achievement. Flare-up was defined
as an exacerbation of the disease characterized by a occurrence/
recurrence of neurological manifestations and/or a recurrence of
thrombocytopenia (,100610
9/L at least 2 days) and/or a
worsening of thrombocytopenia without any other identifiable
cause, before the achievement of a durable remission.
Statistical Analysis
Continuous variables were summarized by mean (standard
deviation). Wilcoxon rank-sum test was used to compare
continuous variables, and chi-square test or Fisher exact test was
used to compare binary data. Data were analyzed using SAS 9.1
(SAS Institute, Cary NC).
We developed an algorithm to predict severe ADAMTS13
deficiency at clinical presentation. Variables significantly associat-
ed with severe ADAMTS13 deficiency were tested in multivariate
logistic regression with stepwise selection [22]. Selected continuous
variables were dichotomized with reference to the threshold
maximizing the Youden Index (sensitivity plus specificity minus
one) and then rounded to the nearest easy-to-recall value. Two
predictive binary scores were calculated: 1) a score minimizing the
number of false-positive diagnoses (ie, high specificity and positive
predictive value) taking the value of 1 when all criteria were
positive, and 0 otherwise; 2) a score minimizing the number of
false-negative diagnoses (ie, high sensitivity and negative predictive
value) taking the value of 1 when at least one criterion was positive,
and 0 otherwise.
Internal validation of the algorithm was performed by the
bootstrap resampling technique [23]. Five hundred samples were
drawn with replacement from the original data set, of the same size
and event probability as the original data set. The predictive
performance was assessed by the median (95% confidence interval)
of the following indicators: 1) area under the receiver operating
characteristic curve (AUROC) where AUROC varied between 0.5
and 1.0 (the higher, the better); 2) specificity, sensitivity, and positive
and negative predictive values of the two predictive binary scores.
Results
The Registry included 361 patients with TMA, of which 118
had an associated condition and 243 were idiopathic. Twenty-nine
patients were excluded because of insufficient collected data,
leaving 214 patients for analysis.
Severe ADAMTS13 deficiency occurred in 155 patients. Five
additional patients had a mild ADAMTS13 deficiency that ranged
from 13% to 18% with a detectable plasma inhibitor (1 case) or
with anti-ADAMTS13 antibodies (4 cases) as assessed by ELISA.
Overall, 160 patients (74.8%) were referred to as the deficient
group. ADAMTS13 deficiency was acquired in all investigated
cases (Figure 1). In the remaining 54 of 214 patients (25.2%),
referred to as the detectable group, the mean ADAMTS13 activity
was 51.4 (29)% (Figure 2). Among these patients, anti-
ADAMTS13 antibodies were sought in 10 cases (including 4
patients with ADAMTS13 activity ranging from 20% to 35%) and
were below the positive threshold level.
Table 1 details the clinical characteristics of the 214 patients
according to ADAMTS13 activity. There was no association
between ADAMTS13 activity and sex, weight, CNS involvement,
autoimmune disease and fever. Patients in the deficiency group
were younger (P,.001).
Hemoglobin levels were slightly lower (P=.06) and reticulocyte
count was higher (P,.0001) in patients in the deficiency group
(Table 2). Levels of LDH were comparable in both groups.
Thrombocytopenia was more profound in patients in the
deficiency group (P,.0001). Serum creatinine level was higher
in patients in the detectable group (P,.0001), and estimated GFR
was lower (P,.0001). Patients in the deficiency group were more
likely to have detectable ANA (P,.001) (Table 2). Antinuclear
antibodies (ANA) titers were apparently comparable between both
groups (not shown) and ranged from 1:80 (36 patients) to 1:5000 (3
patients), through 1:160 (17 patients), 1:320 (15 patients), 1:640 (12
patients), 1:1280 (11 patients) and 1:2560 (1 patient). Titers were
unavailable for 3 patients.
Survival, time to durable platelet count recovery, and plasma
volumes infused until durable complete remission were compara-
ADAMTS13 Deficiency in TMA
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(P=.73, .36 and .15, respectively; Table 3). However, patients in
the detectable group more frequently experienced end-stage renal
disease following the TMA episode (P,.0001). Steroids and
vincristine were used more frequently in patients in the deficiency
group (P=.001 and P=.06, respectively) and splenectomy was
performed equally in both groups.
Table 3. Treatment and Outcome in 214 Patients with
Thrombotic Microangiopathy According to ADAMTS13 Activity.
In the deficiency group, 27 patients received 2 infusions (4 cases),
3 infusions (2 cases), or 4 infusions (21 cases) of rituximab for
refractory disease (8 cases), flare-up (11 cases), or chronic relapsing
disease with persistent acquired severe ADAMTS13 deficiency (8
cases). Two patients died at 17.5 (3.5) days despite 2 salvage
infusions of rituximab. The remaining patients recovered platelet
count after 25.1 (15) days. Five patients experienced a relapse 1
(0.72) year following diagnosis, of favorable outcome with PE and
rituximab. One patient experienced 2 additional relapses 18 and 30
months later, of favorable outcome again with rituximab and PE.
Two patients with a persistent severe ADAMTS13 deficiency after
remission achievement were treated with pre-emptive infusions of
rituximab, allowing a complete recovery of ADAMTS13activity. In
both cases however, ADAMTS13 recovery was transient, which
required additional pre-emptive infusions of rituximab (every ,18
months for 3 and 5 years, respectively). In the 2 remaining patients,
ADAMTS13 activity is persistently normal after 2 and 3 years of
follow-up, respectively.
The incidence of relapse did not clearly differ between both
groups. However, episodes of flare-up were more frequently
observed in patients in the deficiency group (P,.01).
Overall mean follow-up was 17.8 (24.2) months.
Three variables were selected in multivariate logistic regression
to predict severe ADAMTS13 deficiency at clinical presentation
(Table 4): creatinine level, platelet count, and presence of ANA.
The AUROC decreased slightly from 0.951 to 0.930 when
continuous variables were dichotomized at thresholds of
200 mmol/L for creatinine level and 30610
9/L for platelet count.
Internal validation by bootstrap resampling showed a high level of
accurate prediction of the model (median AUROC, 0.911; 95%
CI, 0.868-0.949). When all three criteria were present (creatinine
level #200 mmol/L, platelet count #30610
9/L, and positive
ANA), specificity was 98.1% (95% CI, 94.4–100%), and positive
predictive value was 98.7% (95% CI, 96.4–100%), minimizing the
number of false-positive diagnoses. When at least one criterion was
present (creatinine level #200 mmol/L, platelet count #30610
9/
L, or positive ANA), sensitivity was 98.8% (95% CI, 96.9–100%),
and negative predictive value was 93.3% (95% CI, 85.2–100%),
minimizing the number of false-negative diagnoses (Table 5).
In the original data set, only one patient was classified as a false
positive using all three criteria (ie, detectable ADAMTS13 activity
despite positive ANA, platelet count #30610
9/L, and creatinine
level #200 mmol/L), and results of testing for anti-ADAMTS13
antibodies by ELISA were negative. In contrast, 2 patients were
classified as false negative using all three criteria (ie, severe
ADAMTS13 deficiency despite negative ANA, platelet count
.30610
9/L and creatinine level .200 mmol/L). Serum creati-
nine level #200 mmol/L and platelet count #30610
9/L had the
stronger association with a severe ADAMTS13 deficiency
(Adjusted Odds ratio .20 and 9, respectively). By using those 2
criteria, we had a very low number of misclassified patients.
Indeed, 6 patients with detectable ADAMTS13 activity were
classified as a false-positive diagnosis of ADAMTS13 deficiency. In
addition, 3 patients with a deficient ADAMTS13 activity were
classified as false-negative diagnoses of ADAMTS13 deficiency.
Discussion
TMA are rare diseases and only registries allowing the analysis
of several hundreds of patients may be the basis of reliable data
about pathophysiologic, diagnostic and therapeutic issues. The
strengths of our study include consistency in evaluation and
management (that is, we included patients within a limited period
Figure 1. Survey of ADAMTS13 inhibitor and anti-ADAMTS13 antibodies on diagnosis in patients with a severe (,5%) or a mild
(13–18%) ADAMTS13 deficiency.
doi:10.1371/journal.pone.0010208.g001
Figure 2. ADAMTS13 value on diagnosis. Dark grey squares: deficient ADAMTS13 activity with inhibitory or non-inhibitory anti-ADAMTS13
antibodies; light grey squares: deficient ADAMTS13 activity with suspected inhibitory or non-inhibitory anti-ADAMTS13 antibodies; white squares:
detectable ($20%) ADAMTS13 activity. Grey area delimits ADAMTS13 values of normal subjects. Abbreviation: TMA, thrombotic microangiopathy.
doi:10.1371/journal.pone.0010208.g002
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consensual national recommendations, determined ADAMTS13
activity in a central laboratory, and recorded their data
prospectively) and the large number of centers and medical
specialties that participated in patient recruitment, which provided
a large, representative sample of patients with idiopathic TMA
and their different clinical aspects.
ADAMTS13 activity has been validated as a crucial criteria for
TMA diagnosis [1] and it may also be useful in the future for the
guidance of first and second line therapeutic options. However, at
short term, the measurement of ADAMTS13 in emergency is
unlikely to be available in all hospitals. Therefore, the primary
objective of our study was to try to establish a predictive score for
severe ADAMTS13 deficiency based on standard biological
Table 1. Clinical Characteristics of 214 Patients with Thrombotic Microangiopathy According to ADAMTS13 Activity.
Deficiency group (n=160) Detectable group (n=54) P Value
Previous TMA episode 13 (8%) 5 (9%) .98
Autoimmune disease 27 (17%)
1 7 (13%)
2 .64
Family history of autoimmune disease 26 (16%) 10 (19%) .86
Age, y 39.4 (15.5) 50.6 (19.9) ,.001
Body weight, kg 69.9 (18.4) 66.1 (14.0) .15
Female 118 (74%) 42 (78%) .56
Fever 51 (32%) 14 (26%) .39
Ethnicity
3
North Africans 26 (17%) 0 (%) -
Other Caucasians 116 (75%) 48 (89%) .01
Afro-Caribbeans 12 (8%) 2 (4%) -
CNS involvement 94 (59%) 35 (65%) .43
Headache 37 (23%) 7 (13%) -
Confusion 29 (18%) 9 (17%) -
Seizure 11 (7%) 14 (26%) -
Focal deficiency 38 (24%) 11 (20%) -
Coma/vigilance disturbance 28 (18%) 17 (31%) -
Data are presented as mean (standard deviation) or number (percent).
1Systemic lupus erythematosus (5 cases); idiopathic thrombocytopenic purpura (3 cases); autoimmune endocrinopathies (type 1 diabetes: 2 cases; autoimmune
thyroiditis: 1 case); ankylosing spondylitis(2 cases); ulcerative colitis (2 cases), and 1 case each of cutaneous lupus, liver granulomatosis, chronic polyarthritis, psoriasis,
juvenile chronic polyarthritis, primary biliary cirrhosis, primary Raynaud phenomenon, eczema, livedo, urticaria, lichen planus, and celiac disease.
2Autoimmune thyroiditis (2 cases); and 1 case each of rheumatoid arthritis, Crohn disease, psoriasis, type 2 cryoglobulinemia, and Sneddon syndrome.
3After exclusion of 2 patients of other origin and 8 patients with undisclosed origin.
Abbreviations: CNS, central nervous system; TMA, thrombotic microangiopathy.
doi:10.1371/journal.pone.0010208.t001
Table 2. Results of Laboratory Testing in 214 Patients with Thrombotic Microangiopathy According to ADAMTS13 Activity.
Deficiency group (n=160) Detectable group (n=54) P Value
Hemoglobin level, g/dL 8.1 (2.2) 8.7 (2.1) .06
Reticulocyte count, 610
9/L 185 (118) 106 (80.1) ,.0001
LDH level, U/L 6.0 (4.6) 5.8 (3.5) .70
Platelet count, 610
9/L 17.4 (14.2) 66.6 (49.3) ,.0001
Creatinine level, mmol/L
mg/dL
114 (68.4)
1.29 (0.77)
454 (326)
5.13 (3.68)
,.0001
Estimated GFR, mL/min 80.6 (33.3) 35.0 (59.2) ,.0001
ANA 85 (53%)
1 13 (24%)
2 ,.001
Anti-dsDNA antibodies 9 (7%)
3 0 (0%)
4 .21
Anticardiolipin antibodies 14 (11%)
3 9 (20%)
5 .11
Data are presented as mean (standard deviation) or number (percent).
121 patients had anti-extractable nuclear antigen antibodies, including anti-SSA antibodies in 12 cases, anti-SSA antibodies associated with anti-SSB antibodies in 5
cases, and anti-U1-snRNP antibodies in 4 cases.
21 patient had anti-SSA antibodies.
The analysis was performed on 127
3,3 5
4 and 45
5 patients.
Abbreviations: ANA, antinuclear antibodies; Anti-dsDNA, anti-double-stranded DNA; GFR, glomerular filtration rate.
doi:10.1371/journal.pone.0010208.t002
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the differences we identified between patients with ADAMTS13
deficiency and those with a detectable ADAMTS13 activity
($20%) (ie, serum creatinine level, platelet count and, to a lesser
extent, ANA positivity) may therefore rapidly identify patients with
acquired, immune-mediated ADAMTS13 dysfunction. Of partic-
ular interest, creatinine level #200 mmol/L and platelet count
#30610
9/L had the stronger association with a severe
ADAMTS13 deficiency. By using those 2 criteria, we had a
remarkably low number of misclassified patients. Interestingly, we
noted that all 3 misclassified patients with a severe renal failure
who finally had a deficient ADAMTS13 activity were $55-year-
old. Since the mean age at TTP diagnosis is usually the fourth
decade, this result suggests that older patients may be a risk factor
of developing severe renal failure despite ADAMTS13 deficiency.
Further studies should thus specifically assess the presentation of
patients $55-year-old to establish whether age influences clinical
presentation in TTP.
Our secondary objective was to focus on idiopathic TMA
presentation and short term outcome as a function of ADAMTS13
level (severe or mild deficiency/detectable activity) in order to see
if a pathophysiology-based classification could be relevant for
therapeutic management. In this work, we failed to associate
ADAMTS13 activity with survival. This result contrasts with some
previous reports which associated detectable ADAMTS13 activity
with an increased death rate [8,17,24–26]; for review, see [10]).
However, these discrepancies may be explained by the fact that we
excluded from the analysis TMA associated with other conditions
(transplantation, cancer and chemotherapy or HIV infection),
which are usually associated with detectable ADAMTS13 activity
and a very poor prognosis. Indeed, when only idiopathic TMA are
considered, it is likely that ADAMTS13 activity does not
distinguish survivors from non survivors.
Importantly, in our study, patients with detectable ADAMTS13
activity had a frequent evolution to end-stage renal disease, similar
to patients with HUS [16,17]. Indeed, idiopathic TMA with
detectable ADAMTS13 activity share features of atypical HUS
and antiphospholipid syndrome [27] and probably includes
various subsets of diseases with distinct pathophysiological
mechanisms that require now to be clearly identified. For example,
we cannot exclude that a dysfunction in complement proteins may
be involved in some of these patients, which may account for the
14% relapse rate we observed. Similarly, the incidence of
malignant hypertension or microangiopathic antiphospholipid-
associated syndrome, a more recently identified form of TMA
[27], remains to be determined in those patients. Last, it is
noteworthy that 31 out of 54 patients with a detectable
ADAMTS13 activity had a moderate decrease in the protein
activity that ranged from 20% to 50%, as it was reported in
various autoimmune diseases or other conditions [28,29]. In these
patients, we cannot totally exclude that a subtle dysfunction in
ADAMTS13 by yet unknown mechanisms may also have a role in
the TMA process.
Surprisingly, we observed no significant difference in term of
plasma volume or time to platelet count recovery between the 2
groups of patients. This may be explained by the use of rituximab
in 27 patients within the subgroup with a deficient ADAMTS13,
though we cannot totally exclude a possible additional role of
steroids since patients in the deficiency group received more
frequently steroids than patients of the detectable group. Indeed, it
is likely that, with only standard plasma-exchange-based treat-
ment, these 27 patients may have required longer treatment
duration and may have needed more time to achieve a normal
platelet count. However, interestingly, we confirm here that
ADAMTS13 activity is of prognostic value since an acquired
Table 4. Association Between Patient Characteristics and
ADAMTS13 Deficiency Using Multivariate Analysis.
Patient Characteristics
Adjusted
Odds Ratio 95% CI P Value
Creatinine level #200 mmol/L
(2.26 mg/dL)
23.4 8.8–62.5 ,.001
Platelet count #30610
9/L 9.1 3.4–24.2 ,.001
Positive ANA 2.8 1.0–8.0 ,.05
Abbreviations: ANA, antinuclear antibodies; CI, confidence interval by bootstrap
resampling technique.
doi:10.1371/journal.pone.0010208.t004
Table 3. Treatment and Outcome in 214 Patients with
Thrombotic Microangiopathy According to ADAMTS13
Activity.
Deficiency
group (n=160)
Detectable
group (n=54) P Value
Plasma volume, mL/kg
1 762 (678) 686 (759) .15
Steroids
2 130 (81%) 32 (59%) .001
Rituximab
3 27 (17%) 0 (0%) -
Vincristine 35 (22%) 5 (9%) .06
Splenectomy 7 (4%) 1 (2%) .66
Time to platelet count
recovery, days, median
(25
th–75
th percentile)
16 (7–27) 11 (5–38) .36
Survival 142 (89%) 47 (87%) .73
Flare-up episode(s) 76 (51%) 13 (26%) ,.01
Relapse
4 28 (20%) 7 (14%) .37
ESRD 0 (0%) 10 (21%) ,.0001
Data are presented as mean (standard deviation) or number (percent).
1Plasma volume refers to plasma volume infused until durable complete
remission.
2Posology was 1 to 1.5 mg/kg/day for 3 weeks, with a subsequent progressive
decrease within the following weeks.
3Four 375 mg/m2 infusions were performed within 2 to 3 weeks immediately
after a PE session.
4The incidence rate (%) was calculated by dividing the number of patients who
relapsed by the number of survivors.
Abbreviation: ESRD, end-stage renal disease.
doi:10.1371/journal.pone.0010208.t003
Table 5. Internal Validation to Predict Severe ADAMTS13
Deficiency at Clinical Presentation.
At Least 1 Positive
Criterion
All 3 Criteria
Positive
Sensitivity 98.8 (96.9–100) 46.9 (41.3–53.1)
Specificity 48.1 (38.9–59.3) 98.1 (94.4–100)
Positive predictive value 85.0 (82.6–87.7) 98.7 (96.4–100)
Negative predictive value 93.3 (85.2–100) 38.6 (35.8–41.9)
Data are provided as median percent with 95% confidence interval.
doi:10.1371/journal.pone.0010208.t005
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frequent flare up episodes of the disease despite intensive
treatment (for review, see [10]). Those exacerbations are
associated with an increased duration of hospitalization stay and
with an increased therapy-related morbidity [30], and they
represent a typical current indication of additional therapies such
as rituximab, aimed at reducing the number of plasma exchange
sessions and treatment duration [11–14].
In conclusion, we provide here an original and reliable
diagnostic score involving platelet count and serum creatinine
level to predict severe acquired ADAMTS13 deficiency on
diagnosis. Of course, this score is not intended to substitute for
measuring ADAMTS13 activity, which remains mandatory both
to confirm the pathophysiology of the TMA and to validate
retrospectively initial therapeutic management. In addition, using
a large cohort of patients with idiopathic TMA, we emphasized
that a pathophysiology-based classification is likely to be more
relevant than a clinical presentation-based classification to predict
the short term outcome. Thus, at the very initial step of patient
management, this score may be very helpful to identify patients
liable to experience exacerbations of the disease during standard
treatment and thus potentially requiring early immunomodula-
tory drugs. This subgroup of specific patients may be a good
target for future therapeutic assays goaled to evaluate the
accurate timing of immunomodulation in the therapeutic scheme
of TMA.
Supporting Information
Figure S1 Pathophysiological mechanisms leading to micro-
thrombi and organ failure in TTP. The blood smear shows
schistocytes (black arrows) as a consequence of thrombi and very
high shear stress in microcirculation.
Found at: doi:10.1371/journal.pone.0010208.s001 (0.12 MB TIF)
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